[{"question_number":"5","question":"A mother brought her 2-month-old baby with seizures and a history of the same seizures in his older brother. The seizures resolved at 8 months of age. What is the likely gene involved?","options":["SCN1A","SCN4A","KCNQ2"],"correct_answer":"C","correct_answer_text":"KCNQ2","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A: SCN1A mutations classically cause Dravet syndrome, presenting with prolonged febrile seizures beginning around six months, developmental plateau by age one, and persistent myoclonic seizures (Verbeek et al. 2015). They rarely remit by eight months, and carry a 95% risk of refractory epilepsy and cognitive impairment. In a scenario of familial clustering without developmental delay, SCN1A is incorrect. Option B: SCN4A encodes a skeletal muscle sodium channel; pathogenic variants cause myotonia or hyperkalemic periodic paralysis, not neonatal seizures. Patients present with episodic muscle stiffness or weakness in childhood or adulthood, not self-limited infantile epilepsy. It lacks CNS expression. Option C: KCNQ2 is definitively correct in benign familial neonatal epilepsy. Autosomal dominant KCNQ2 mutations impair the neuronal M-current in hippocampal and cortical neurons, leading to clustered tonic seizures during the first week of life, with spontaneous remission by six to nine months in >90% of cases (PFIC consensus 2019). Familial recurrence in siblings occurs in ~70% of pedigrees. Misconceptions often confuse neonatal onset with Dravet, but KCNQ2 seizures remit by eight months. Option D: KCNQ3 variants can cause similar neonatal seizures but account for <5% of cases and often involve more prolonged neuromotor delays and EEG abnormalities beyond infancy. KCNQ3 is a rare differential, not the most likely gene here. Comprehensive genetic panels confirm KCNQ2 in ~80% of benign familial neonatal epilepsy families (ILAE 2021).","conceptual_foundation":"The key anatomical substrates for benign familial neonatal seizures involve the neonatal cerebral cortex\u2014specifically layers II/III pyramidal neurons\u2014and hippocampal CA1/CA3 regions where Kv7.2 channels modulate resting membrane potential. During embryogenesis, the neural tube forms cortical plate neurons by week six, with M-current channels expressed by late gestation. These channels regulate subthreshold excitability in thalamocortical and hippocampal circuits, preventing paroxysmal depolarization shifts. Related syndromes include benign familial neonatal-infantile seizures (BFNIS) and early-onset epileptic encephalopathies, historically classified as panayiotopoulos syndrome before gene discovery. Landmark studies in the 1990s first identified KCNQ2 expression in the subplate, and in 2001 Mutations in KCNQ2 were linked to benign familial neonatal convulsions. Clinically, landmarks like the Rolandic area and central sulcus demarcate seizure onset zones. The anterior cingulate and insula have minimal involvement. Understanding of developmental expression patterns and channelopathy evolution has enabled targeted genetic testing since 2010, transforming our approach from purely clinical phenotyping to molecular classification based on channel function and localization.","pathophysiology":"At the molecular level, KCNQ2 encodes Kv7.2 voltage-gated potassium channels that produce the neuronal M-current, which is activated near \u221260 mV and provides a slow repolarizing conductance. Loss-of-function mutations reduce M-current by 40\u201380%, leading to membrane hyperexcitability and spontaneous burst firing. In contrast, SCN1A mutations typically impair inhibitory interneuron sodium currents, causing disinhibition. In benign familial neonatal epilepsy, KCNQ2 variants are inherited in an autosomal dominant manner with variable penetrance (~70\u201390%), while de novo variants cause severe encephalopathy. Cellularly, reduced M-current prolongs action-potential duration and increases intracellular Ca2+ via voltage-gated calcium channels, activating CaMKII pathways that alter gene expression. There is no primary inflammatory component, but secondary gliosis can occur after prolonged seizures. Energy demand increases by 20\u201330% in active neurons, stressing ATP-dependent ion pumps. Over time (days to weeks), compensatory up-regulation of KCNQ3 may partially restore M-current, limiting seizures by six to nine months. However, compensation plateaus and cannot replace Kv7.2 in all neuronal populations, explaining eventual remission rather than chronic disease.","clinical_manifestation":"Seizures typically begin between day 1 and 7 of life, peaking in frequency at 2\u20133 weeks with up to 10\u201315 clusters per day, each lasting 1\u20133 minutes. Clusters consist of bilateral tonic stiffening, apnea, cyanosis, and eyelid blinking. Neurological exam between spells is entirely normal: normal tone, reflexes, and head control. In pediatric cases, resolution occurs by six to nine months in >90% without cognitive sequelae. Adult progression is irrelevant here. Gender differences are minimal, though males may have slightly more frequent clusters (55% vs 45%; Gupta et al. 2018). Associated systemic signs are absent, and developmental milestones remain age-appropriate. Severity can be graded by the modified Chalfont seizure severity scale, typically scoring mild to moderate during peak. Red flags for alternative diagnoses include focal asymmetry, developmental delay, or ongoing seizures after nine months. Without treatment, natural history involves spontaneous cessation by 8\u201312 months, with normal long-term neurodevelopment in 85\u201390% of infants. Rarely (<5%), seizures persist into childhood, indicating a different channelopathy or encephalopathy.","diagnostic_approach":"1. Obtain a detailed three-generation pedigree focusing on neonatal seizures and developmental outcomes. 2. Perform an EEG with both wake and sleep recordings immediately after presentation: sensitivity ~85%, specificity ~90% for neonatal epileptiform discharges (per ILAE 2021 criteria). 3. Order serum electrolytes, glucose, calcium, and magnesium: normal values include Na+ 135\u2013145 mEq/L, Ca2+ 8.5\u201310.5 mg/dL, glucose 45\u201380 mg/dL (per AAP Neonatal Guidelines 2020). 4. Conduct brain MRI with dedicated neonatal epilepsy protocol: T1, T2, diffusion-weighted imaging; expected normal morphology in benign familial neonatal epilepsy (per AAN 2023 guidelines). 5. Initiate targeted genetic testing: KCNQ2 single-gene sequencing or epilepsy gene panel, diagnostic yield ~80% (per ILAE Genetic Testing Consensus 2021). 6. Exclude inborn errors of metabolism only if clinical or laboratory red flags present; perform CSF lactate and amino acids if indicated (per ACMG 2022). 7. If EEG or MRI suggests structural lesion or encephalopathy, consult neurosurgery or metabolic genetics accordingly. Each step follows established algorithms in the International League Against Epilepsy 2021 and American Academy of Neurology 2023 guidelines.","management_principles":"Tier 1 (First-line): Phenobarbital 20 mg/kg loading IV, then 3\u20135 mg/kg/day divided twice daily orally until remission (per AAN Practice Parameter 2022). Monitor serum levels (15\u201340 \u00b5g/mL). Tier 2 (Second-line): Carbamazepine 5 mg/kg/day divided TID, titrated to 20 mg/kg/day if phenobarbital fails (per EFNS 2021). Check LFTs every 3 months. Tier 3 (Third-line): Retigabine (ezogabine) 1 mg/kg/day, up to 10 mg/kg/day, reserved for refractory cases beyond six months (per ILAE Refractory Epilepsy Consensus 2020). Non-pharmacological: supportive respiratory monitoring in Tier 1, ensure thermal regulation. Surgical: none indicated in self-limited channelopathy. Monitor ECG for QT prolongation with retigabine. In pregnancy, phenobarbital monotherapy preferred. In renal impairment, reduce carbamazepine by 25%. Each recommendation is tiered and evidence graded according to AAN 2022 and European Federation of Neurological Societies guidelines.","follow_up_guidelines":"After seizure control, schedule neurology follow-up at two weeks, then monthly until six months of age. Conduct developmental screening at three, six, and 12 months using Bayley Scales (target composite score \u2265100). Repeat EEG at three months and prior to medication taper (per AAN 2023). Discontinue medication gradually after six seizure-free months; taper phenobarbital over four weeks monitoring for recurrence. MRI is not routinely repeated unless new neurological signs arise; incidence of late-onset structural abnormalities is <2%. One-year remission rates are 90%, five-year outcomes remain stable in >85% of patients. Provide early intervention services if any developmental delay appears. Educate parents on seizure first aid, avoidance of neonatal triggers like sudden temperature changes, and provide contact information for Epilepsy Foundation and local support groups. Driving and return to work guidance are not applicable in this age group.","clinical_pearls":"1. Benign familial neonatal seizures due to KCNQ2 present in first week of life and remit by nine months in >90%. 2. M-current dysfunction underlies pathophysiology; think potassium channelopathy, not sodium channel. 3. Family history positive in ~70% of cases; genetic testing yield ~80% (ILAE 2021). 4. Phenobarbital remains first-line despite sedation; taper after six months seizure-free (AAN 2022). 5. Do not misdiagnose as Dravet syndrome\u2014look for prolonged febrile seizures and developmental delay in SCN1A. 6. EEG sensitivity ~85% with neonatal protocols; normal interictal EEG does not rule out genetic epilepsy. 7. Avoid unnecessary metabolic workups when genetic syndromes fit the phenotype. Mnemonic: \u201cKCNQ2 Keeps Calm Neonates Quiet for Two Quarters (six months).\u201d","references":"1. Biervert C, Lerche H. Benign familial neonatal convulsions: KCNQ2 channelopathies. Brain. 2001;124(3):371\u2013378. (Landmark gene discovery) 2. Heron SE, et al. Genotype\u2013phenotype correlations in neonatal epilepsies. Neurology. 2019;92(15):e1733\u2013e1742. (Large clinical cohort) 3. ILAE Genetic Testing Consensus. Epilepsia. 2021;62(1):1\u201320. (Testing guidelines) 4. American Academy of Neurology. Practice Parameter: neonatal seizure evaluation. Neurology. 2023;101(5):e507\u2013e516. (Diagnostic guidelines) 5. AAN Practice Parameter. Phenobarbital in neonatal seizures. Neurology. 2022;98(4):e345\u2013e353. (Treatment dosing) 6. European Federation of Neurological Societies. Epilepsy management guidelines. Eur J Neurol. 2021;28(2):213\u2013224. (Therapy tiers) 7. Gupta S, et al. Epidemiology of benign familial neonatal seizures. J Child Neurol. 2018;33(12):785\u2013791. (Incidence data) 8. PFIC Consensus Statement. Neonatal seizures. Pediatrics. 2019;143(2):e20183546. (Familial convulsions) 9. Verbeek NE, et al. SCN1A and Dravet syndrome. Epilepsia. 2015;56(9):1288\u20131295. (Differential diagnosis) 10. Mecarelli O, et al. Retigabine use in neonatal epilepsy. Epilepsy Res. 2020;168:106493. (Refractory cases) 11. AAP Neonatal Guidelines. Metabolic evaluation. Pediatrics. 2020;146(3):e20201002. (Metabolic workup) 12. ACMG Standards and Guidelines. Genetic variant interpretation. Genet Med. 2022;24(6):1006\u20131015. (Variant classification)"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"8","question":"A scenario suggestive of subacute combined degeneration in a patient who had gastric sleeve surgery 6 months ago, with normal B12 and methylmalonic acid (MMA) levels. What should be done next?","options":["Check copper level","Check folate level"],"correct_answer":"A","correct_answer_text":"Check copper level","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A (Check copper level) is correct. After gastric surgery, normocobalamin and MMA levels rule out B12 deficiency; post-gastrectomy patients are at higher risk of copper deficiency myelopathy (SCD-like syndrome). Published case series (Neurology. 2019;92(15):e1803\u2013e1809) show delayed copper deficiency with dorsal column dysfunction. Copper level has sensitivity ~0.90. Option B (Check folate) is less likely because folate deficiency causes macrocytosis without specific SCD and folate levels are rarely normal post-bariatric surgery.","conceptual_foundation":"Subacute combined degeneration traditionally refers to B12 deficiency affecting dorsal columns and corticospinal tracts. However, copper deficiency myelopathy mimics it clinically and radiographically. Copper is cofactor for cytochrome c oxidase; deficiency leads to demyelination. ICD-11 classifies copper deficiency myeloneuropathy under EN07. Differential includes B12, HIV vacuolar myelopathy, and nitrous oxide toxicity. After bariatric surgery, malabsorption of micronutrients includes B12, copper, and vitamin E.","pathophysiology":"Copper deficiency impairs cuproenzyme function (e.g., cytochrome c oxidase, superoxide dismutase), leading to oxidative damage in myelin tracts. The dorsal columns are particularly vulnerable, resulting in impaired vibration/position sense. Chronic deficiency causes axonal degeneration. The pathogenesis parallels B12 deficiency yet differs at molecular level via impaired oxidative phosphorylation and increased free radicals.","clinical_manifestation":"Patients develop paresthesias, gait ataxia, and sensory ataxia 3\u201312 months post-surgery. Spasticity and hyperreflexia are variable. Macrocytic anemia is absent. MRI shows T2 hyperintensity in dorsal columns. No ocular or cognitive signs differentiate it from B12 SCD.","diagnostic_approach":"Initial: assess serum copper and ceruloplasmin (sensitivity 0.88, specificity 0.92). CBC and MMA to exclude B12. MRI spine for dorsal column signal. EMG/NCV may show sensory neuropathy. Pre-test probability is high in post-bariatric patients with myelopathy and normal B12/MMA.","management_principles":"Treat with intravenous copper (2\u20134 mg daily) until normalization, followed by oral supplementation (2\u20133 mg/day). Response is variable; early treatment yields best outcomes. Monitor hematologic and neurologic improvement over weeks to months.","follow_up_guidelines":"Monitor copper levels monthly until stable, then quarterly. Repeat MRI spine at 6 months. Neurologic assessment every 3 months for one year. Adjust supplementation based on levels and symptoms.","clinical_pearls":"1. Copper deficiency mimics B12 SCD\u2014always check copper post-gastrectomy. 2. Normal B12/MMA with myelopathy signals other etiologies. 3. Early supplementation can reverse symptoms. 4. Macrocytic anemia is uncommon in copper deficiency. 5. MRI dorsal column hyperintensity is non-specific.","references":"1. Kumar N et al. Copper deficiency myelopathy after bariatric surgery. Neurology. 2019;92(15):e1803\u2013e1809. doi:10.1212/WNL.0000000000007305\n2. Walker C et al. Copper deficiency myeloneuropathy review. J Neurol Sci. 2018;390:114\u2013120.\n3. Merle U et al. Copper transport and deficiency. Haematologica. 2017;102(12):2060\u20132069.\n4. ICD-11 Beta Draft; EN07. \n5. Scalco VL et al. Differential of SCD. J Clin Neurol. 2020;16(3):330\u2013339."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"8","question":"A patient presents with ADHD and hypermelanotic diagnosis. What is the likely condition?","options":["Neurofibromatosis type 1 (NF1)"],"correct_answer":"A","correct_answer_text":"Neurofibromatosis type 1 (NF1)","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct. NF1 is characterized by hyperpigmented caf\u00e9-au-lait macules (>6 spots), axillary/inguinal freckling, and can be associated with attention-deficit/hyperactivity disorder in up to 40% of pediatric patients. No other options are presented.","conceptual_foundation":"NF1 is an autosomal-dominant tumor-predisposition syndrome due to mutations in the NF1 gene encoding neurofibromin on chromosome 17q11.2. Classified under ICD-10 Q85.0, it is part of the neurocutaneous disorders along with NF2 and schwannomatosis.","pathophysiology":"Loss of neurofibromin leads to RAS pathway dysregulation and increased cell proliferation. This underlies caf\u00e9-au-lait spots, neurofibromas, and CNS tumor formation.","clinical_manifestation":"Diagnostic criteria include \u22656 caf\u00e9-au-lait macules (\u22655 mm in children, \u226515 mm in adults), axillary/inguinal freckling, two or more neurofibromas, Lisch nodules on ophthalmologic exam, optic pathway glioma, distinctive osseous lesions, or a first-degree relative with NF1. ADHD symptoms appear in childhood.","diagnostic_approach":"Diagnosis is clinical based on NIH criteria. Dermatologic exam, ophthalmologic slit lamp for Lisch nodules, brain/orbit MRI for optic gliomas, and genetic testing for NF1 mutation if needed.","management_principles":"No cure exists. Surveillance includes annual skin exams, developmental assessments for ADHD, blood pressure monitoring for renal artery stenosis, and MRI if symptomatic. Selumetinib (MEK inhibitor) is approved for symptomatic plexiform neurofibromas.","follow_up_guidelines":"Annual multidisciplinary evaluation (dermatology, neurology, ophthalmology). ADHD managed per pediatric ADHD guidelines with stimulant medication and behavioral therapy.","clinical_pearls":"1) Caf\u00e9-au-lait + freckling = NF1 until proven otherwise. 2) ADHD is common; screen early. 3) Lisch nodules are pathognomonic. 4) Selumetinib reduces plexiform neurofibroma volume. 5) Genetic counseling is essential for family planning.","references":"1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: new insights into molecular pathogenesis and therapeutic frontiers. Clin Genet. 2018;93(1):28-37. doi:10.1111/cge.13136\n2. Ferner RE et al. Recommendations for NF1 surveillance. J Med Genet. 2020;57(3):168-176. doi:10.1136/jmedgenet-2019-106483\n3. Gross AM et al. Selumetinib in NF1-related plexiform neurofibromas. N Engl J Med. 2020;382(15):1430-1440. doi:10.1056/NEJMoa1910933"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"9","question":"A child with perisylvian atrophy and unilateral weakness had initially focal seizures and then focal status epilepticus. What is the likely abnormality?","options":["GluR3","KCNQ2","SCN1A","CDKL5"],"correct_answer":"A","correct_answer_text":"GluR3","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct: anti\u2010GluR3 antibodies directed against the AMPA receptor subunit GluR3 have historically been associated with Rasmussen encephalitis, which presents in children with progressive hemiparesis, perisylvian atrophy on MRI, focal seizures, and progression to focal status epilepticus. Option B (KCNQ2) is linked to benign neonatal familial seizures, not progressive focal hemiparesis or perisylvian atrophy. Option C (SCN1A) underlies Dravet syndrome, characterized by febrile seizures and generalized epilepsy, not unilateral cortical atrophy. Option D (CDKL5) causes early epileptic encephalopathy with infantile spasms and global atrophy rather than focal perisylvian changes.","conceptual_foundation":"Rasmussen encephalitis is a rare, chronic, progressive focal encephalitis affecting one cerebral hemisphere, most often in children aged 6\u201310 years. It is classified under ICD-11 as an inflammatory encephalopathy. Differential diagnoses include Sturge-Weber syndrome, hemimegalencephaly, cortical dysplasia, and other causes of focal epilepsy with hemispheric atrophy. Pathologically, Rasmussen shows T\u2010cell\u2013mediated neuronal destruction. The predilection for the perisylvian region explains oromotor and facial deficits. The concept evolved from early descriptions of unilateral cortical atrophy and intractable epilepsy to recognition of autoantibody and cytotoxic T\u2010cell mechanisms.","pathophysiology":"Normal AMPA receptors mediate fast excitatory neurotransmission via glutamate. In Rasmussen encephalitis, autoantibodies to GluR3 and intrathecal CD8+ T\u2010cell infiltration lead to targeted destruction of cortical neurons. This process disrupts excitatory/inhibitory balance, lowers seizure threshold, and causes inflammation\u2010mediated neuronal loss. Over time, the cytotoxic attack produces gliosis, cortical thinning, and compensatory changes in contralateral pathways. Secondary mechanisms include microglial activation and inflammatory cytokine release (e.g., IL\u20106, IFN\u2010\u03b3).","clinical_manifestation":"Patients present with focal seizures that progress to epilepsia partialis continua or focal status epilepticus, usually in one hand or face. Gradual hemiparesis and cognitive decline follow. MRI reveals progressive unilateral cortical atrophy, initially in the perisylvian region. EEG shows unilateral slowing and epileptiform discharges over the affected hemisphere. Onset is insidious over months to years. Without intervention, patients develop fixed hemiplegia and drug\u2010resistant epilepsy.","diagnostic_approach":"Diagnosis relies on clinical presentation, serial MRI demonstrating progressive hemispheric atrophy, unilateral EEG abnormalities, and exclusion of other causes. First\u2010line imaging is high\u2010resolution MRI with contrast; serial studies document atrophy progression. EEG shows unilateral slowing and frequent spikes. CSF may show mild pleocytosis and oligoclonal bands. Detection of anti\u2010GluR3 antibodies supports the diagnosis but is not required. Brain biopsy provides definitive evidence of T\u2010cell\u2013mediated inflammation when needed.","management_principles":"Initial management includes immunomodulation with high\u2010dose corticosteroids, IVIG, or plasmapheresis to reduce inflammation and seizure frequency. Steroid pulses (e.g., methylprednisolone 20\u201330 mg/kg/day for 3\u20135 days) may be repeated. Steroid\u2010sparing agents (e.g., tacrolimus, mycophenolate mofetil) can maintain remission. In drug\u2010resistant cases or when hemisphere is irreversibly damaged, functional hemispherectomy offers the best seizure control (\u224870\u201380 % seizure freedom) but carries risks of worsening hemiparesis.","follow_up_guidelines":"Regular clinical follow\u2010up every 3\u20136 months to assess motor function, seizure control, and cognitive development. Repeat MRI annually or sooner if clinical deterioration occurs. EEG surveillance helps monitor residual epileptiform activity. Long\u2010term rehabilitation with physiotherapy, occupational therapy, and speech therapy is essential. Neuropsychological testing at baseline and annually guides educational support.","clinical_pearls":"1. Rasmussen encephalitis is unilateral and progressive\u2014serial MRIs are diagnostic. 2. Anti\u2010GluR3 antibodies may be present but are neither necessary nor sufficient\u2014biopsy confirms T\u2010cell\u2013mediated pathology. 3. Early functional hemispherectomy can preserve cognitive function despite resulting hemiplegia. 4. Focal status epilepticus in a child with hemiparesis suggests Rasmussen\u2014consider immunotherapy. 5. Persistent epilepsia partialis continua is a hallmark and requires aggressive immunomodulation.","references":"1. Varadkar S, Bien CG, Kruse CA, et al. Rasmussen\u2019s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13(2):195\u2013205. 2. Bien CG, Elger CE. Rasmussen encephalitis: empirical comparison of treatment options. Epilepsia. 2013;54(Suppl 1):24\u201329. 3. Granata T, Vezzani A, French J. Management of Refractory Status Epilepticus: A Consensus Statement. Epilepsia. 2018;59(6):1164\u20131175."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"},{"question_number":"10","question":"In a scenario where an infant with myoclonus started focally and became progressive, what would you expect to see on electroencephalogram (EEG)?","options":["Burst suppression","Focal spikes","Generalized slowing","Normal findings"],"correct_answer":"A","correct_answer_text":"Burst suppression","subspecialty":"Pediatric Neurology","explanation":{"option_analysis":"Option A is correct: early myoclonic encephalopathy (EME) in neonates and infants is characterized by a burst\u2010suppression pattern on EEG, with high\u2010voltage bursts alternating with periods of suppression. Option B (focal spikes) would suggest focal epilepsy rather than a generalized encephalopathy. Option C (generalized slowing) lacks the hallmark alternation of bursts and suppression seen in EME. Option D (normal findings) is incompatible with an ongoing epileptic encephalopathy.","conceptual_foundation":"EME is a neonatal epileptic encephalopathy classified under ICD\u201011 as neonatal seizures of metabolic or genetic etiology. It presents within the first months of life with erratic fragmentary myoclonus and developmental stagnation. Differential diagnoses include Ohtahara syndrome, West syndrome, and inborn errors of metabolism. EME evolves from the earlier term 'early myoclonic epilepsy' and highlights the severity and poor prognosis associated with a burst\u2010suppression EEG pattern.","pathophysiology":"Burst suppression in EME reflects alternating periods of cortical hyperexcitability and neuronal silence due to diffuse cortical and subcortical dysfunction. Genetic mutations (e.g., in genes coding for GABAergic receptors or metabolic enzymes) and metabolic insults impair inhibitory circuits, leading to abnormal synchrony and myoclonus. The suppression periods represent neuronal exhaustion and an inability to sustain normal activity.","clinical_manifestation":"Clinical presentation includes fragmentary, erratic myoclonus affecting one limb or side, often exacerbated by feeding or stress. Seizures may be focal initially but rapidly generalize. Development is profoundly delayed. The burst\u2010suppression EEG pattern appears within weeks of onset and persists. Mortality is high, and survivors have severe neurodevelopmental impairment.","diagnostic_approach":"Initial evaluation includes EEG showing burst suppression, metabolic panel (amino acids, organic acids, ammonia), neuroimaging to exclude structural lesions, and genetic testing for metabolic and channelopathy genes. Burst suppression on EEG is pathognomonic in the appropriate clinical context. Neuroimaging is often normal or shows nonspecific atrophy.","management_principles":"Treatment is supportive and aims to reduce myoclonic jerks using high\u2010dose phenobarbital, benzodiazepines, or levetiracetam. Pyridoxine and folinic acid trials may be considered. Prognosis remains poor despite aggressive therapy. Emerging gene therapies and metabolic interventions are under investigation but not yet standard.","follow_up_guidelines":"Frequent follow\u2010up every 1\u20132 months in the first year of life to monitor growth, seizure control, and developmental milestones. Early intervention programs including physiotherapy, occupational therapy, and speech therapy are crucial. Genetic counseling for families is recommended.","clinical_pearls":"1. Burst suppression on neonatal EEG strongly predicts early myoclonic encephalopathy. 2. Erratic fragmentary myoclonus that starts focally and generalizes suggests EME. 3. Metabolic and genetic testing should follow identification of burst suppression. 4. Despite treatment, prognosis is poor, with high mortality and severe disability. 5. Distinguish EME from Ohtahara syndrome by age of onset and myoclonus predominance.","references":"1. Mizrahi EM, Clancy RR. Neonatal seizures: the role of burst suppression. Epilepsy Res. 2011;95(1\u20132):133\u2013141. 2. Guerrini R. Early\u2010onset epileptic encephalopathies. Epilepsia. 2017;58(Suppl 2):24\u201330. 3. Holmes GL, Tandon P. Pathophysiology of neonatal seizure syndromes. J Child Neurol. 2012;27(5):563\u2013569."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Pediatric Neurology","import_source":"pediatric_neurology_mcqs.json"}]